Papers by Deepak L. Bhatt
Page 5 · newest first
- Perspectives on Artificial Intelligence in Medical Publishing: A Survey of Medical Journal Editors2025
- Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor TherapyArteriosclerosis Thrombosis and Vascular Biology · 2025
- Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.2025
- Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular MortalityJACC Advances · 2025
- Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITEuropean Journal of Preventive Cardiology · 2025
- Association between lipoprotein(a) and cardiovascular events in patients with peripheral artery disease: the Mass General Brigham Lp(a) registry.2025
- Trials on Timing of Cardiovascular Medication AdministrationJACC Advances · 2025
- Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MIESC Heart Failure · 2025
- Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE‐TIMI 58ESC Heart Failure · 2025
- Representation of Older Adults and Women in Randomized Trials of Noninvasive Imaging for Chest PainCirculation Cardiovascular Imaging · 2025
- Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial InfarctionJACC Heart Failure · 2025
- Cardiovascular-Focused Messaging to Improve Influenza Vaccination RatesNEJM Evidence · 2025
- Rapid Titration of Heart Failure Therapies by EtiologyJACC Heart Failure · 2025
- In-Hospital Mortality in Hemorrhagic Myocardial InfarctionNEJM Evidence · 2025
- Eicosapentaenoic acid (EPA) limits the more rapid oxidation of lipoprotein(a) [Lp(a)] compared with other ApoB particlesCardiovascular Research · 2025
- Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES TrialJournal of the American Heart Association · 2025
- Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trials.2025
- Perspectives on Artificial Intelligence in Medical Publishing: A Survey of Medical Journal EditorsJournal of Cardiovascular Pharmacology · 2025
- Fully Automated Diagnosis of Acute Myocardial Infarction Using Electrocardiograms and Multimodal Deep LearningJACC Advances · 2025
- First myocardial infarction: risk factors, symptoms, and medical therapyEuropean Heart Journal · 2025
- Impact of Sex and Age on Trends of Mortality From Infective Endocarditis in High-Income CountriesJACC Advances · 2025
- Burden and severity of respiratory syncytial virus infection in adults with cardiovascular diseases: A systematic literature reviewProgress in Cardiovascular Diseases · 2025
- International expert consensus on surgery for type 2 diabetes mellitusBMC Endocrine Disorders · 2025
- Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarctionNature Cardiovascular Research · 2025
- P2Y₁₂inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trialsBMJ · 2025
- One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programmeEuroIntervention · 2025
- Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1–induced platelet reactivityScience Translational Medicine · 2025
- Differential effect of triglycerides on the prognosis of patients with a first versus recurrent acute coronary syndromeEuropean Journal of Clinical Investigation · 2025
- Acute coronary syndromes: mechanisms, challenges, and new opportunitiesEuropean Heart Journal · 2025
- Percutaneous Coronary Intervention Outcomes by 5 Major Race and Ethnic SubgroupsJACC Advances · 2025
- An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor AgonistsENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2025
- Representation of Older Adults and Women in Randomized Trials of Non-Invasive Imaging for Chest Pain2025
- Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) RegistrySHILAP Revista de lepidopterología · 2025
- Performance of PREVENT equations for cardiovascular risk prediction in young patients with myocardial infarction: From the MGB YOUNG-MI registryAmerican Journal of Preventive Cardiology · 2025
- Outcomes Following Minimally Invasive Surgery for Intracerebral Hemorrhage in the AHA Get With The Guidelines-Stroke RegistryStroke · 2025
- Quantifying the Unknowns of Plaque Morphology: The Role of Topological Uncertainty in Coronary Artery DiseaseMayo Clinic Proceedings Digital Health · 2025
- Multi-instance learning with attention mechanism for coronary artery stenosis detection on coronary computed tomography angiographyEuropean Heart Journal - Digital Health · 2025
- Cardiometabolic risk factors and disease trends for atrial fibrillation in individuals with type 1 diabetes: a nationwide registry studyCardiovascular Diabetology · 2025
- Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 monthsEuropean Heart Journal · 2025
- Emerging Pathways of Action of Eicosapentaenoic Acid (EPA)JACC Basic to Translational Science · 2025
- Clinical practice patterns among older multimorbid adults presenting with suspected ischemic symptoms: A multi-center surveyAmerican Heart Journal Plus Cardiology Research and Practice · 2025
- Long-Term, Patient-Level Analysis of Radiofrequency Renal Denervation in the SYMPLICITY Clinical Trial ProgramJACC Advances · 2025
- Variation in Likelihood of Undergoing Percutaneous Coronary Intervention for ST‐Segment–Elevation Myocardial Infarction Among US HospitalsSHILAP Revista de lepidopterología · 2025
- Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized TrialJournal of the American Heart Association · 2025
- Emerging agents targeting triglyceridesCurrent Opinion in Lipidology · 2025
- Patient Enrollment for Cardiovascular Clinical Trials in the United StatesJAMA Cardiology · 2025
- Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndromeEuropean Journal of Preventive Cardiology · 2025
- Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized TrialDiabetes Care · 2025
- Expanding the triglyceride range in clinical trials: therapeutic opportunitiesEuropean Heart Journal · 2025
- Clinical significance of a new diagnosis of atrial fibrillation in patients with vascular diseaseHeart Rhythm · 2025